Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 138 results for sclerosis

  1. Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

    Awaiting development Reference number: GID-TA11721 Expected publication date: TBC

  2. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

  3. Renal replacement therapy and conservative management (NG107)

    This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.

  4. Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (IPG681)

    Evidence-based recommendations on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in adults. This involves spraying the inside of the peritoneal cavity with chemotherapy.

  5. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

  6. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)

    Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.

  7. Percutaneous laser therapy for fetal tumours (IPG180)

    Evidence-based recommendations on percutaneous laser therapy for fetal tumours. This involves inserting a needle through the mother's abdomen to the tumour and using laser energy to shrink it.

  8. Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis (IPG640)

    Evidence-based recommendations on percutaneous venoplasty for chronic cerebrospinal venous insufficiency in people with multiple sclerosis. This involves inserting an inflatable balloon into veins in the neck and chest in an attempt to widen them.

  9. Infantile spasms: Does treatment response relate to cause in infantile spasms? Does early treatment success in seizure control and resolution of the hypsarrhythmic EEG influence the long-term developmental and cognitive outcomes more than the underlying cause of the spasms?

    steroids over vigabatrin, although this excluded children with tuberous sclerosis. This study provided no specific subgroup analysis...

  10. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

  11. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

  12. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

  13. Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)

    This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.

  14. Glatiramer acetate depot for multiple sclerosis [TSID10620]

    Topic prioritisation

  15. Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]

    Topic prioritisation